Lucia Kim
Overview
Explore the profile of Lucia Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
655
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Seo Y, Prome S, Kim L, Han J, Kim J, Choi S
J Hematop
. 2024 Jan;
17(1):17-22.
PMID: 38175380
No abstract available.
12.
Seo Y, Prome S, Kim L, Han J, Kim J, Choi S
J Hematop
. 2024 Jan;
17(1):1-15.
PMID: 38175379
Agarose-based cell block (CB) technique can be modified to be combined with the frozen section technique for the preparation of a high-quality frozen-embedded CB (F-CB) from an effusion or fine-needle...
13.
Ryu W, Cha H, Park M, Kim J, Choi J, Kim L, et al.
Front Oncol
. 2022 Nov;
12:900966.
PMID: 36330497
Crizotinib is an oral selective small-molecular tyrosine kinase inhibitor (TKI) that suppress the activity of anaplastic lymphoma kinase (ALK) and ROS1 kinases, as well as mesenchymal-epithelial transition. The cumulative clinical...
14.
Lee S, Hong S, Woo J, Lee J, Kim K, Kim L, et al.
J Comput Biol
. 2022 Jun;
29(9):987-1000.
PMID: 35749140
Several tools have been developed for calling variants from next-generation sequencing (NGS) data. Although they are generally accurate and reliable, most of them have room for improvement, especially regarding calling...
15.
Lee Y, Lim J, Ryu W, Park M, Kim L, Kim K, et al.
Transl Lung Cancer Res
. 2021 Jul;
10(6):2539-2550.
PMID: 34295660
Background: Evidence of the clinical impact of programmed death-ligand 1 (PD-L1) expression in small cell lung cancer (SCLC) is scarce and conflicting, even though atezolizumab became the first PD-L1 inhibitor...
16.
Chang S, Shim H, Kim T, Choi Y, Kim W, Shin D, et al.
J Pathol Transl Med
. 2021 May;
55(3):181-191.
PMID: 33966368
Molecular biomarker testing is the standard of care for non-small cell lung cancer (NSCLC) patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean Molecular Pathology Study Group...
17.
Kim J, Kim M, Lee K, Lee R, Kim L
Medicine (Baltimore)
. 2021 May;
100(18):e25692.
PMID: 33950950
Introduction: The relationship between chronic empyema and malignant tumors, most of which are lymphoma, has been recognized for many decades. Sarcomatoid carcinoma associated with chronic empyema is extremely rare, may...
18.
Lim J, Oh S, Kim L, Suh Y, Ha Y, Kim J, et al.
Transl Lung Cancer Res
. 2021 Apr;
10(3):1221-1230.
PMID: 33889504
Background: The programmed cell death pathway necroptosis may synergize with the DNA damage response (DDR) in opposing tumor progression. While our basic mechanistic understanding of the necroptotic cell death advances...
19.
Lee J, Choi S, Kim L, Park I, Han J, Kim J
Pol J Pathol
. 2020 Jul;
71(2):146-154.
PMID: 32729305
Modified agarose cell-block (CB) technique can be effectively used to have the CB embedded in the OCT compound for the preparation of frozen CB (F-CB) sections in the same way...
20.
Lee H, Kim L, Kim C, Kim J, Nam H, Ryu J
Respir Med Case Rep
. 2020 Jun;
30:101086.
PMID: 32489848
Ground glass opacities, consolidation, and pleural effusions are observed in herpes simplex virus (HSV) pneumonia. Neither necrosis nor cavitation has been reported in areas of parenchymal disease. We describe a...